Important Safety Information Do not use AOD-9604 if you: Have a known hypersensitivity to growth hormone fragments or any component of the formulation Have active malignancy (cancer that is currently being treated or monitored) Are pregnant or breastfeeding (insufficient safety data) Have a history of severe allergic reactions to peptide therapies Common side effects (typically mild and transient): Headache, mild gastrointestinal disturbances (flatulence, mild diarrhea at higher doses), upper respiratory tract symptoms, injection site reactions (redness, mild discomfort) Seek medical attention if you experience: Signs of allergic reaction (hives, difficulty breathing, swelling of face or throat), persistent gastrointestinal symptoms, unexplained significant changes in energy, mood, or physical symptoms Clinical Safety Data Safety studies involving approximately 900 participants across six randomized controlled trials documented that AOD-9604 displayed a very good safety and tolerability profile indistinguishable from placebo across most parameters

Laboratory assays for hCG: what should we measure and how
High-performance living demands focus and energy
There is no published, peer-reviewed, full-paper randomised human trial with accessible results showing that BPC-157 is effective or safe for any indication
Comparing nasal spray to other delivery methods Understanding how nasal spray fits into the broader landscape of peptide delivery helps researchers choose the optimal method for their specific goals
Should I Be Concerned About High Vitamin B12 Levels